Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Cardiology-CTVS
  • Cardiology & CTVS Perspective
  • Hypertension and...

Hypertension and Kidney: Choosing the Right Therapeutic Agent for BP Control and Nephroprotection

Written By : Dr. Arun Shah |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2020-11-11T11:30:42+05:30  |  Updated On 11 Nov 2020 3:49 PM IST
Hypertension and Kidney: Choosing the Right Therapeutic Agent for  BP Control and Nephroprotection
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

In the management of hypertension, the treatment goals need to be dual with equal emphasis – i.e. to reduce the blood pressure levels and provide effective nephro-protection. Such treatment goals can be achieved and sustained over long periods of time by considering agents that work effectively and safely on lowering blood pressure, and at the same time have independent action on nephro-protection at the time of initiation of treatment. Newer generation calcium channel blockers like cilnidipine may offer specific clinical benefits, beyond just blood pressure-lowering effect, which in turn, could improve long term renal & cardiovascular outcomes.

It is well established that there is a strong relationship between hypertension and chronic kidney disease (CKD). Hypertension is an important cause of End-Stage Renal Disease (ESRD), contributing to the disease itself or, most commonly, responsible for its progression. (1) The prevalence of both, and of the associated burden on cardiovascular morbidity and mortality, has significantly increased globally (2) Statistics from several renal databases have identified systemic hypertension as the second most common cause of End-Stage Renal Disease (ESRD), after Diabetes mellitus (3)

Studies have indicated that compared with patients with a blood pressure level < 140/90 mm Hg, those with a blood pressure level ≥ 160/95 mm Hg had an average -2.67 mL/min/1.73m 2 greater annual decline in estimated glomerular filtration rate and a 5.21-fold greater risk of early kidney function decline. (4)
While the exact mechanisms of kidney damage in patients with hypertension remain elusive, two complementary pathogenic processes leading to kidney fibrosis and scarring seem plausible. First, changes in systemic and renal macro and microvasculature leading to the loss of renal autoregulation causing elevation of intraglomerular capillary pressure and consequent hyperfiltration-mediated injury. Such hyperfiltration leads to trans glomerular loss of proteins causing the release of cytokines and growth factors by mesangial cells and downstream tubular epithelial cells.
Second is endothelial dysfunction and loss of endogenous vasodilators as precipitating factors of hypoxic-ischemic injury. This sequel leads to activation of intrarenal Renin-Angiotensin System (RAS) and an increased release of cytokines and growth factors with recruitment of inflammatory cells, which stimulate apoptosis and cause loss of normal kidney cells, increased matrix production, ultimately leading to progressive glomerular and interstitial fibrosis and scarring. (5) Additionally, the sympathetic nervous system activity is also increased in chronic kidney disease (CKD) (6) . Afferent signals from the diseased kidney are transmitted to the vasomotor control centre in the brain increasing the blood pressure (7) .
The treatment of hypertension has three main goals: blood pressure control; preventing the progression of CKD itself; and reducing the risk of cardiovascular complications (1)
Studies have cited that >75% hypertensive patients require two or more medications to achieve blood pressure goals, with observations supporting that most patients should consider treatment with a renin‐angiotensin system blocker combined with a calcium channel blocker as first‐line therapy or as part of the overall therapeutic regimen (8) with recent global hypertension guidelines also endorsing single-pill combination as initial therapy for effective management of hypertension.
Cilnidipine – a newer generation Calcium Channel Blocker (CCB), possesses both L- and N-type calcium channel blocking activity. Since N-type calcium is distributed along the nerve and in the brain, cilnidipine is anticipated to exert specific action on nerve activity, such as inhibition of the sympathetic nervous system (9) Sympatholytic profiles of cilnidipine have been observed in vitro as well as in clinical practice (10). In a study conducted in 2920 hypertensive patients, treatment with cilnidipine and angiotensin receptor blocker led to significant reductions in heart rate, particularly in patients with a higher baseline heart rate
≥
75 beats/min, and was associated with few adverse reactions related to central nervous functions. (11)
The major clinical benefit of N-type calcium channel blocking the activity of cilnidipine is demonstrated in the form of preventing the progression of proteinuria which is superior to amlodipine in patients with hypertension and chronic renal disease when added with a renin-angiotensin system inhibitor (12)
In summary, cilnidipine – dual type (L- and N-type) calcium channel blocker seems to be valuable first-line choice of antihypertensive agent for the management of hypertension as initial therapy for optimising long term – renal and cardiovascular outcomes in these patients.
The above article has been published under the MD brand connect Initiative. To read more about cilnidipine, click here
References
Adapted from
1 Elsa Morgado and Pedro Leão Neves (2012). Hypertension and Chronic Kidney Disease: Cause and Consequence – Therapeutic Considerations, Antihypertensive Drugs, Prof. Hossein Babaei (Ed.), ISBN: 978-953-51-0462-9, InTech, Available from:
http://www.intechopen.com/books/antihypertensivedrugs/hypertension-in-chronic-kidney-disease-cause-and-consequence-therapeutic-considerations-
2 Schoenborn, C. (2009). Health characteristics of adults aged 55 years and over: United States, 2004–2007. Natl Health Stat Report, Vol. 8, No. 16, (July, 2008), pp. 1-31
3 US Renal data System, USRDS 2010 Annual report: Atlas of Chronic Kidney Disease and End-stage Renal Disease in the United States, NIH, NIDDKD, 2010
4 Suma Vupputuri et al, Effect of Blood Pressure on Early Decline in Kidney Function Among Hypertensive Men, Hypertension. 2003; 42:1144-1149.)
5 Goldblatt, H. (1964). Hypertension of renal origin. Historical and experimental background. American Journal of Surgery, Vol. 107, (January, 1964), pp. 21-25.
6 Converse, R.L. (1992). Sympathetic overactivity in patients with chronic renal failure. N Engl J Med, Vol. 327, No. 27, (December, 1992), pp.1912-1918
7 Rump, L.C. (2000). Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uremia? Nephrol Dial Transplant 2000; Vol. 15, No. 11, (November, 2000), pp. 1735-1738
8 Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, Velazquez E, Weber M, Zappe DH, Hau T, Jamerson KA. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. J Am Heart Assoc. 2018 Jan 4;7(1):e006940. doi: 10.1161/JAHA.117.006940. PMID: 29301757; PMCID: PMC5778960.
9 Fujii S, Kameyama K, Hosno M, Hayashi Y, Kitamura K. Effect of cilnidipine, a novel dihydropyridine calcium channel antagonist, on N type calcium channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther. 1997;280:1184e1191
10 Uneyama H, Takahara A, Dohmoto H, Yashimoto R, Inoue K, Akaike N. Blockade of N type calcium current by cilnidipine (FRC 8653) in acutely dissociated rat sympathetic neurones. Br J Pharmacol. 1997;122:37e42
11 Nagahama S, Norimatsu T, Maki T, Yasuda M, Tanaka S. The effect of combination therapy with L/N type calcium channel blocker cilnidipine, & an angiotensin II receptor blocker on blood pressure & heart rate in Japanese hypertensive patients: an observational study conducted in Japan. Hypertens Res. 2007;30:815e822
12 Fujita T, Ando K, Nishimura H, et al. For cilnidipine versus amlodipine randomised trial for evaluation of renal diseases(CARTER) study investigators. Antiproteinuric effect of calcium channel blocker cilnidipine added to rennin angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int. 2007;72:1543e1549.The

The author, Dr Arun Shah is a practicing Nephrologist in the city of Mumbai, Maharashtra and is presently associated as Consultant Nephrologist at Lilavati Hospital, Mumbai, Bharatiya Arogya Nidhi Hospital, Mumbai and Hinduja Healthcare ,Khar, Mumbai

hypertensionkidneyblood pressurenephroprotectionchronic kidney diseaserenal diseasediabetes mellitusbpbp controlkidney stone
Dr. Arun Shah
Dr. Arun Shah

    Dr Arun Shah is a practicing Nephrologist in the city of Mumbai, Maharashtra and is presently associated as Consultant Nephrologist at Lilavati Hospital, Mumbai, Bharatiya Arogya Nidhi Hospital, Mumbai and Hinduja Healthcare ,Khar, Mumbai.

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    Aspirin in Primary Prevention- When to Consider?

    Aspirin in Primary Prevention- When to Consider?

    Featured image representing medico legal

    What's the Role of Expert Opinion in Medical Negligence?

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    View All

    Journal Club Today

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    View All

    Health News Today

    Health Bulletin 09/ May/ 2025

    Health Bulletin 09/ May/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok